September 30, 2005
Via EDGAR
Amy Bruckner
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
| | | | | |
| | | Re: | | Introgen Therapeutics, Inc. |
| | | | Annual Report on Form 10-K for the year ended December 31, 2004 |
| | | | Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 |
| | | | File No. 000-21291 |
Dear Ms. Bruckner:
On behalf of Introgen Therapeutics, Inc. (“Introgen” or the “Company”), we hereby inform you that on or before October 7, 2005 Introgen intends to file a further response to comments from the Staff of the Securities and Exchange Commission received by letter dated August 9, 2005 relating to Introgen’s Annual Report on Form 10-K for the year ended December 31, 2004 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2005.
If you have any additional questions or comments, please feel free to contact Chris Ozburn at (512) 338-5414 or me at (512) 338-5420.
| | | | | |
| | | Sincerely, | | |
| | | WILSON SONSINI GOODRICH & ROSATI,
Professional Corporation | | |
| |
| | | /s/ ALAN BICKERSTAFF Alan Bickerstaff | | |
| | | |
| cc: | | Jim B. Rosenberg, Securities and Exchange Commission(via EDGAR) |
| | Joel Parker, Securities and Exchange Commission(via EDGAR) |
| | Jim Albrecht, Introgen Therapeutics, Inc.(via facsimile) |
| | Alan Bickerstaff |
